The EBMT的动态

Spesolimab, a humanized antibody targeting IL-36, offers a new treatment option for patients with generalized pustular psoriasis (GPP). This video dives into how spesolimab’s mechanism directly targets the IL-36 receptor to prevent flare-ups and manage GPP symptoms long-term. Find out more about this innovative therapy and how it’s helping patients worldwide! Watch here: https://hubs.ly/Q02WYdx90 #GPP #Spesolimab #PsoriasisTreatment

Last month in April 2024, Arvinas entered into a transaction with Novartis, including a Global License Agreement for the Development and Commercialization of ARV-766 for the treatment of Prostate Cancer. Findings during the ASCO 2024 conference revealed that ARV-766, an investigational PROTAC androgen receptor degrader, exhibited encouraging clinical activity alongside manageable toxicity in patients with metastatic castration-resistant prostate cancer (mCRPC). In a Phase I/II study involving pretreated mCRPC patients, ARV-766 demonstrated favorable tolerability and promising clinical efficacy, particularly in individuals with tumors harboring AR LBD mutations. These results underscore the potential of ARV-766 as a valuable addition to the armamentarium for advanced prostate cancer, warranting further development and investigation. Discover Expert Insights and In-Depth Analysis with DelveInsight's Exclusive ASCO 2024 Coverage @ https://lnkd.in/ggacy4En #asco #asco24 #asco2024 #ascoconference #Arvinas #Novartis #GlobalLicenseAgreement #ARV766 #ProstateCancerTreatment #PROTAC #AndrogenReceptorDegrader #ClinicalActivity #ManageableToxicity #mCRPC #PhaseI_IIStudy #TumorResponse #ARLBDMutations #AdvancedProstateCancer #ClinicalEfficacy #DrugDevelopment #CancerResearch #OncologyInnovation #PersonalizedMedicine #HealthcareAdvances #ScienceNews #MedicalBreakthrough #Pharmaceuticals

On August 22nd, Alkermes announced the initiation of the Vibrance-2 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with narcolepsy type 2 (NT2). "We are pleased to initiate Vibrance-2, a phase 2 clinical study for adults with narcolepsy type 2, based on the data from our phase 1, proof-of-concept study in this patient population. ALKS 2680 is the most advanced investigational orexin 2 receptor agonist currently in development for narcolepsy type 2," said Craig Hopkinson, M.D., Chief Medical Officer and Executive Vice President, Research & Development at Alkermes. "Across narcolepsy type 1 and narcolepsy type 2, significant unmet need remains, and we look forward to further characterizing the efficacy and safety profile of ALKS 2680 in the Vibrance studies in both of these important patient populations." Read the full article at: https://lnkd.in/eCZBfH_x #narcolepsy #sleepdisorder #phase2 #clinicaltrial #Alkermes

How dexamethasone protects against severe COVID-19 Dexamethasone was used as an effective drug for severe COVID cases during the pandemic. A study integrating single-cell and bulk transcriptomics in clinical cohorts reveals the molecular basis of its immunomodulatory effect and also provides a framework for the future development of companion diagnostics for patient stratification in precision medicine. The authors show that dexamethasone-induced transcriptional changes were confined to a specific monocyte state and molecular treatment responses in monocytes were directly linked to clinical outcome. They also found that reversal of dysregulated monocyte signatures in dexamethasone-treated COVID-19 survivors and monocyte single-cell signatures stratified blood samples could be used for treatment response. #sciencenewshighlights #ScienceMission https://lnkd.in/gbhz_5rp https://lnkd.in/gpMi5dY6

New study uncovers how GPCRs, particularly the vasopressin V2 receptor (V2R), continue to signal from internalized compartments, highlighting the role of βarrestin (βarr) and Gβγ in non-canonical endosomal signaling. Discover how these mechanisms can pave the way for innovative therapeutic strategies. Check out the latest GPCR news in the Ecosystem today! You’ll need to register, but don’t worry, it’s Free! ??https://bit.ly/4d9yUQ3 #GPCR #DrGPCR

In ERA 2024's best-ranked abstract, we presented 72-week eGFR stabilization from our Phase 2b clinical trial for #IgANephropathy. We also showed rapid hematuria improvement and significantly higher hematuria resolution compared to placebo during the 36-week randomized period. Read the press release here: https://lnkd.in/eRcDMqd5 #ERA24

We are thrilled to announce our collaboration with Paradigm Medical Communications to offer the first activity of an insightful CME course: "Psoriasis Prime Time: The Role of TYK Inhibition in Psoriasis." In this edition, our expert faculty will: ?Review the unique mechanism of action for allosteric tyrosine kinase 2 (TYK2) inhibitors compared with Janus kinase inhibitors. ?Highlight the efficacy and safety data for the new TYK2 inhibitor in psoriasis. ?Use a case-based discussion to illustrate how TYK2 inhibition can be incorporated into psoriasis treatment. Join us to stay at the forefront of psoriasis management and enhance your clinical practice. https://lnkd.in/gxVjwXmR

Now in BJUI from BJUI and BJUI Compass journals: authors Prof. Dr. Axel S. Merseburger and Dr. Simon Chowdhury report on the association between ultralow prostate-specific antigen decline and outcomes in the Phase 3 TITAN study of patients with metastatic hormone-sensitive #ProstateCancer. For US #HCPs.

QTc and QRS liabilities are a serious concern when developing novel clinical compounds. Assessment of ion channel activity provides a robust method to highlight potential risks, however it may not be sufficient to capture all potential mechanisms that could induce QTc, QRS or arrhythmia issues. In such cases an integrated system such as the hiPSC-derived cardiomyocyte (hiPSC-CM) model can be a valuable model. Our reliable and reproducible translational human cardiovascular assays demonstrate the cardiac safety of your therapeutic compounds in line with current and future CiPA and FDA guidelines. https://hubs.la/Q02N873c0 #cardiacrisk #cardiacsafety #drugdiscovery

Today, at the second day of #ADLM2024, I am excited to have time with our valued customers talking about how they’re using our advanced @TheBindingSite assays to diagnose and monitor #MultipleMyeloma and immune system disorders. The Binding Site, 12-time winners of the ADLM abstract awards will also be presenting the following abstracts: · Implications of native protein conformation in the IgM quantification: total Ig vs HLC methods comparison with @LuisaCampos, PhD, The Binding Site, part of @ThermoFisherScientific. · Evaluation of patients with monoclonal gammopathy of undetermined significance using Optilite? Freelite? assays with @GabriellaLakos, MD, The Binding Site, part of Thermo Fisher Scientific. #ADLM2024, #diagnostics, #innovation, #MultipleMyeloma